This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A third discussion of the new covid vaccines targeting omicron variant, with a focused look at the potential of Ocugen's first in class nasal vaccine
Ticker(s): OCGN, PFE, MRNA, JNJWho's the expert?
Institution: Mednax
- Pediatric critical care physician
- Neonatal specialist who practices in large urban setting ICUs in Atlanta, GA
- currently sees 1-5 pediatric patients daily in his setting due to COVID-19
Interview GoalGoal of this interview is to discuss the bivalent covid vaccines targeting the omicron variant and the potential of Ocugen's nasal vaccine
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
